Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
- Biotechnology
- Disease
- Drug Discovery
- Vaccine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 544
Technology –The term Technology shall mean (a) any United States or foreign patents that claim two-gene combination cancer vaccines and related technology that issue from, or claim priority to, United States patent application serial number 08/838,702 entitled Combination Immunogene Therapy or United States patent application serial number 09/826,025 entitled Combination Immunogene Therapy (or similar name) and related applications including continuations, continuations-in-part, divisional applications and requests for continuing examination (collectively, the Combination Immunogene Therapy Patent Applications).
IPSCIO Record ID: 415
A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025. The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells. The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF. Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.
IPSCIO Record ID: 26298
IPSCIO Record ID: 3044
During 2003, two lawsuits were filed challenging the Licensor's ownership of this intellectual property. The value of the intellectual property will be diminished if either of the pending lawsuits regarding the same is successful. Governors of the University of Alberta filed against the Licensor and the Licensee in August 2003. The University of Alberta claims, among other things, that the Licensee failed to remit the payment of the University’s portion of the monies paid by the Licensor to the Licensee for the CIT technology purchased by the Licensor.
IPSCIO Record ID: 364016
Licensor also hereby grants to Licensee an exclusive license to make, use, and/or sell the Licensed Materials in the Territory for the Field of Use. At Licensees request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.
U.S. patent application serial number US 61/033,425 entitled 'Heat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 20 March 2008;
PCT patent application number PCT/US2009/001727 entitled 'bleat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 19 March 2009;
all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT patent application number PCT/US2009/001727 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.
“Patent Rights†shall mean the following United States Patent applications U.S. patent application serial number US 61/033,425 entitled “ Allogeneic Cancer Cell-Based Immunotherapy†and files on 3 March 2008; PCT patent application number PCT/US2009/001330 entitled “Allogeneic Cancer Cell-based Immunotherapy†and filed on 3 March 2009; all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT application number PCT/US2009/001330 to meet the requirements of 35 U.S.C. 112¶1; and any re-examination or reissues of the foregoing.
